10x Genomics stock | 2026 forecast, price target & growth

10x Genomics

NasdaqGS:TXG

$ 23,02

+ $1,20 (5,50%)

23,02 $

+$1,20 (5,50%)

End-of-day quote: 04/08/2026

10x Genomics Stock Value

The analyst rating for NasdaqGS:TXG is currently Outperform.

Outperform

10x Genomics Company Info

EPS Growth 5Y

16,35%

Market Cap

$2,79 B

Long-Term Debt

$0,02 B

Short Interest

6,50%

Annual earnings

N/A

Dividend

$0,00

Dividend Yield

0,00%

Founded

2012

Industry

Health Care

Country

United States

ISIN Number

US88025U1097

Website

http://www.10xgenomics.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$20,00

-13.12%

Last Update: 04/09/2026

Analysts: 13

Highest Price Target $25,00

Average Price Target $20,00

Lowest Price Target $17,00

In the last five quarters, 10x Genomics’s Price Target has fallen from $19,57 to $15,07 - a -22,99% decrease. Fourteen analysts predict that 10x Genomics’s share price will fall in the coming year, reaching $20,00. This would represent a decrease of -13,12%.

Top growth stocks in the health care sector (5Y.)

What does 10x Genomics do?

10x Genomics, Inc. operates as a life sciences technology company. The company focuses on building innovative products and solutions to interrogate, understand, and master biology. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. The company has built deep expertise across diverse disciplines, including chemistry, biology, hardware, and software. Innovations in all...

10x Genomics, Inc. operates as a life sciences technology company.

The company focuses on building innovative products and solutions to interrogate, understand, and master biology. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. The company has built deep expertise across diverse disciplines, including chemistry, biology, hardware, and software. Innovations in all of these areas have enabled the deployment of the company's rapidly expanding suite of products, which allow its customers to interrogate biological systems at previously inaccessible resolution and scale. The company's products has enabled researchers to make fundamental discoveries across multiple areas of biology, including oncology, immunology, and neuroscience.

Since launching its first product in mid-2015 through December 31, 2024, the company has sold 7,039 instruments to researchers around the world, including academic and translational researchers, and biopharmaceutical companies.

Portfolios

Resolution and scale are the imperatives that underlie the company's products and technology. The company's solutions are designed to enable understanding biology at the right level of biological resolution, such as at the level of the single cell or at high spatial resolution of tissues and organs. The company's products enable measuring up to millions of single cells or tissue sample positions. Each of the company's platforms is designed to interrogate a major class of biological information, enabling researchers to understand the complexities of biology at a spatial and cellular level. Collectively, the company's platforms enable researchers to interrogate, understand, and master biology at the appropriate resolution and scale.

Single Cell Portfolio

The company's single cell portfolio, powered by its Chromium platform, includes microfluidic chips and related consumables, and its Chromium X Series and legacy Chromium instruments. Chromium enables high-throughput analysis of individual biological components. The company's Chromium instruments serve as precisely engineered reagent delivery systems, partitioning samples into individual components, which can exceed one million. Each partition is paired with proprietary gel beads bearing unique barcodes that allow researchers to identify the contents of each partition and distinguish them from the contents of other partitions. Once biological material in each partition is barcoded, it can then be pooled and sequenced together. Partitioning and barcoding give researchers the ability to measure many discrete biological materials and/or perform many different experiments in parallel, providing tremendous resolution and scale. Chromium enables multiomic readouts, including gene expression, protein (cell surface and intracellular), chromatin, V(D)J, CRISPR/guide RNAs (gRNAs), and antigens, has broad sample compatibility (formalin-fixed paraffin-embedded (FFPE), fresh, fresh frozen, paraformaldehyde (PFA) fixed tissue, DSP/methanol fixed peripheral blood mononuclear cells (PBMCs), and whole blood), and delivers high performance, including high cell recovery rates (CRE), high sensitivity, robustness, and reproducibility.

Spatial Portfolio

The company's spatial portfolio is powered by its Visium and Xenium platforms and aims to bring together the worlds of histology and genomics.

The Visium platform: The company's Visium platform empowers researchers to identify where biological components are located and how they are arranged with respect to each other, otherwise referred to as ‘spatial analysis.’ The Visium platform uses high-density DNA arrays, which have DNA barcode sequences that encode the physical location of biological analytes within a sample, such as a tissue section, allowing the spatial location of the analytes to be ‘read out’ using sequencing to create a visual map of the analytes across the sample. Similar to partitioning, spatial barcoding with large numbers of oligos on an array can unlock tremendous insights, providing high-resolution molecular information to visualize the whole transcriptome and protein expression, paired with same section hematoxylin and eosin (H&E) or infrared (IR) imaging data, across biological tissues.

Xenium platform: The company's Xenium platform for in situ analysis is designed to give scientists the ability not only to locate and type cells in their tissue context, but also to address a variety of specific questions based on previous knowledge of their sample potentially discovered using its Chromium and Visium platforms. The Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing, providing researchers with a detailed map of gene expression patterns without sacrificing resolution or target number.

Software

The company's software is essential to accelerating the mastery of biology. As the company's portfolios unlock new levels of resolution and scale, they generate entirely new types of data at greater volumes and complexity than ever before. Cell Ranger, introduced alongside the company's Chromium platform, has become a trusted scRNA-seq processing pipeline in scientific literature. The company has extended the same principles of accessibility, scalability, and reliability across all its platforms, ensuring that researchers can move from raw data to discovery with ease. Today, the company provides a comprehensive and scalable software ecosystem that supports every stage of the research workflow, from experiment planning to data processing to visualization and exploration. By removing barriers to adoption, the company's tools help researchers generate high-quality data, achieve repeatable success, and seamlessly scale their experiments. Loupe Browser (Chromium and Visium) enables intuitive single-cell, spatial, and multiomic data visualization, helping researchers explore gene expression, cellular interactions, and more—turning complex datasets into interactive insights that accelerate discovery. Xenium Explorer enables intuitive in situ data visualization, allowing researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns with ease. It transforms complex imaging and transcriptomic data into interactive insights, accelerating discovery in spatial biology.

Commercial Organization and Strategy

Since launching its first product in mid-2015, the company has expanded its commercial operations and now sells its products in over 50 countries. The company's customers primarily include academic, government, biopharmaceutical, biotechnology, and other institutions focused on life sciences research. The company sells its products primarily through its own direct sales force in North America and certain regions of Europe. The company sells its products through third-party distributors in certain regions of Asia, Europe, Oceania, Central America, South America, the Middle East, and Africa.

For the year ended December 31, 2024, no single customer, including distributors, represented greater than 10% of the company's business. For the year ended December 31, 2024, sales to academic institutions represented approximately 67% of the company's direct sales revenue.

The company's sales and marketing efforts are targeted at the principal investigators, research scientists, department heads, research laboratory directors, and core facility directors at leading academic institutions, biopharmaceutical companies, and publicly and privately funded research institutions who control buying decisions. The company increases awareness of its products among its target customers through direct sales calls, trade shows, seminars, academic conferences, web presence, social media, and other forms of marketing. The company supplements these traditional marketing efforts by fostering an active online community of users of its products consisting of communities, forums, and blogs with internally generated and user-generated content. The company also provides education and training resources, both online and in person.

Suppliers and Manufacturing

The company's Pleasanton, California, Singapore, and Taiwan manufacturing operations are ISO 9001:2015 certified, which covers design, development, manufacturing, distribution, service, and sales.

Consumables

The majority of the company's consumable products are manufactured at its facilities. These manufacturing operations include, among other operations, gel bead generation, surfactant synthesis, and emulsion oil formulation, reagent formulation and tube filling, certain of the company's microfluidic chips, kit assembly and packaging, as well as analytical and functional quality control testing.

Instruments

The company outsources manufacturing for its Chromium, Visium, and Xenium instruments to qualified contract manufacturers who have represented to the company that they maintain ISO 13485 certification. The company performs optical and final assembly, instrument integration, and testing of its Xenium instrument in-house.

Intellectual Property

Worldwide, the company owned or exclusively in-licensed over 1,290 issued or allowed patents and 1,300 pending patent applications as of December 31, 2024. The company also licenses additional patents on a non-exclusive and/or territory-restricted basis.

The company seeks trademark registration to protect key trademarks, such as its 10X, 10X GENOMICS, CHROMIUM, VISIUM, and XENIUM marks; however, it has not yet registered all of its trademarks in all of its current and potential markets. The company owns registered trademarks on 10X GENOMICS and product-related brand names in the United States and worldwide.

The patents the company owns expire beginning in 2030, and the patents it exclusively in-licenses expire beginning in 2028.

History

The company was founded in 2012. It was incorporated in 2012. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014.

10x Genomics Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Industry Revenues:** - Life Sciences: 100% (2026) **TOP 3 Markets:** - USA: 45% - Europe: 30% - Asia-Pacific: 15% 10x Genomics, Inc. generates all its revenues from the Life Sciences industry, particularly through the sale of instruments and reagents for single-cell and spatial transcriptomics....

At which locations are the company’s products manufactured?

**Production Sites:** Pleasanton, California, USA 10x Genomics, Inc. primarily produces its products in Pleasanton, California. The company has its main production facilities there and develops its technologies and products on site. This strategic location allows the company to operate near key tec...

What strategy does 10x Genomics pursue for future growth?

**Research and Development Investments:** 30% of revenue (2025) **Market Expansion:** Increase international presence by 20% (2025) 10x Genomics, Inc. pursues a growth strategy that heavily relies on innovation and expansion. The company invests significantly in research and development to expand...

Which raw materials are imported and from which countries?

**Main materials:** Microchips, reagents, plastic components **Countries of origin:** USA, China, Germany 10x Genomics, Inc. is a company specializing in the development and production of genomics technologies. The company requires various raw materials and components for the manufacturing of its...

How strong is the company’s competitive advantage?

**Market Share:** 30% (estimated for 2026) **Research & Development Expenses:** $150 million (2025) **Patent Portfolio:** Over 1,000 patents (2025) 10x Genomics, Inc. has gained a significant competitive advantage in the genomics industry, particularly through its innovative technology plat...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Ownership:** 75% (estimated, 2026) **Insider Buys/Sells:** No significant insider transactions in the last year (2026) The institutional investor ownership in 10x Genomics, Inc. is estimated to be around 75%. This indicates a high level of confidence from institutional in...

What percentage market share does 10x Genomics have?

**Market share of 10x Genomics:** Estimated 25% (2026) **Main competitors and their market shares:** 1. **Illumina, Inc.:** 30% 2. **Thermo Fisher Scientific Inc.:** 20% 3. **Becton, Dickinson and Company:** 10% 4. **Agilent Technologies, Inc.:** 8% 5. **Bio-Rad Laboratories, Inc.:** 7% 10x Genomi...

Is 10x Genomics stock currently a good investment?

**Revenue Growth:** 18% (2025) **Research and Development Ratio:** 25% of revenue (2025) **Market Share in Single-Cell Genomics:** 40% (2025) 10x Genomics, Inc. recorded a revenue growth of 18% in 2025, driven by the increasing demand for single-cell genomics technologies. The company is heavily in...

Does 10x Genomics pay a dividend – and how reliable is the payout?

**Dividend:** None (as of 2026) 10x Genomics, Inc. currently does not pay any dividends to its shareholders. The company has historically focused on reinvesting its profits into research and development, as well as into the growth and expansion of its business operations. As 10x Genomics operates...

New support ticket

Explore

10x Genomics Stock Value

10x Genomics Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does 10x Genomics do?

10x Genomics Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

10x Genomics Stock Value

10x Genomics Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does 10x Genomics do?

10x Genomics Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.